The company 23andMe is based out of San Francisco and is now left with a single board member, Wojcicki who controls 49.75 per ...

Consumer DNA testing company 23andMe is circling the drain. The company's CEO, Anne Wojcicki, plans to take the company ...

With 23andme in a desperate situation and eyeing a potential sale, Medical Device Network examines what is set to happen to ...

A giant biotechnology company might be about to go bust. What will happen to the millions of people’s DNA it holds?

Over the past year, 23andMe set new corporate governance lows. CEO Anne Wojcicki now enters de facto “founder mode” after a ...

Once the domain of science fiction, neurotechnology is a reality with enormous implications for medicine and the digital ...

"Most 'wellness companies' test for specific genes. They will produce a report outlining dietary advice based on your genetic ...

Stock splits are typically viewed as bullish indicators that a company sees more growth is on the horizon. Although nothing ...

DNA testing company 23andMe is in financial crisis, raising questions about what will happen to the data it holds on 15 milli ...

Me helped usher in the era of consumer DNA test kits nearly two decades ago, but has more recently faced a series of setbacks ...

The company’s valuation had dropped from $6 billion in 2021, to under $150 million after going public and when CEO Anne Wojcicki pushed for a plan to buy it and take it private, the board rejected her ...